Direct and indirect effects of crisaborole ointment on quality of life in patients with atopic dermatitis: A mediation analysis

Eric L. Simpson; Gil Yosipovitch; Andrew G. Bushmakin; Joseph C. Cappelleri; Thomas Luger; Sonja Ständer; Wynnis L. Tom; William C. Ports; Michael A. Zielinski; Anna M. Tallman; Huaming Tan; Robert A. Gerber

doi:10.2340/00015555-3181

Direct and indirect effects of crisaborole ointment on quality of life in patients with atopic dermatitis: A mediation analysis

Eric L. Simpson, Gil Yosipovitch, Andrew G. Bushmakin, Joseph C. Cappelleri, Thomas Luger, Sonja Ständer, Wynnis L. Tom, William C. Ports, Michael A. Zielinski, Anna M. Tallman, Huaming Tan, Robert A. Gerber

Dermatology

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Crisaborole ointment is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis. Using pooled data from two phase 3 studies (NCT02118766/NCT02118792), mediation modeling determined the interrelationship among pruritus, quality of life (QoL), and treatment. Patients aged ≥ 2 years received crisaborole ointment, 2%, or vehicle twice daily for 28 days. QoL measures were Dermatology Life Quality Index (DLQI) (≥ 16 years) and Children’s Dermatology Life Quality Index (CDLQI) (2–15 years). Pruritus was assessed by the Severity of Pruritus Scale (4-point scale from 0 to 3). The indirect effect of crisaborole on QoL mediated through its effect on pruritus was 51% (DLQI model, p < 0.05) and 72% (CDLQI model, p < 0.05). Direct effect (other effects) on QoL was 49% (DLQI model, p < 0.05) and 28% (CDLQI model, p > 0.05). Mediation modeling shows that crisaborole affects QoL mostly indirectly through pruritus severity reduction.

Original language	English (US)
Pages (from-to)	756-761
Number of pages	6
Journal	Acta dermato-venereologica
Volume	99
Issue number	9
DOIs	https://doi.org/10.2340/00015555-3181
State	Published - Jul 2019

Keywords

Atopic dermatitis
Crisaborole
Mediation
Pruritus
Quality of life

ASJC Scopus subject areas

Dermatology

Access to Document

10.2340/00015555-3181

Cite this

Simpson, E. L., Yosipovitch, G., Bushmakin, A. G., Cappelleri, J. C., Luger, T., Ständer, S., Tom, W. L., Ports, W. C., Zielinski, M. A., Tallman, A. M., Tan, H., & Gerber, R. A. (2019). Direct and indirect effects of crisaborole ointment on quality of life in patients with atopic dermatitis: A mediation analysis. Acta dermato-venereologica, 99(9), 756-761. https://doi.org/10.2340/00015555-3181

Simpson, EL, Yosipovitch, G, Bushmakin, AG, Cappelleri, JC, Luger, T, Ständer, S, Tom, WL, Ports, WC, Zielinski, MA, Tallman, AM, Tan, H & Gerber, RA 2019, 'Direct and indirect effects of crisaborole ointment on quality of life in patients with atopic dermatitis: A mediation analysis', Acta dermato-venereologica, vol. 99, no. 9, pp. 756-761. https://doi.org/10.2340/00015555-3181

@article{e9d6ff33065a4b23b8334051868e264c,

title = "Direct and indirect effects of crisaborole ointment on quality of life in patients with atopic dermatitis: A mediation analysis",

abstract = "Crisaborole ointment is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis. Using pooled data from two phase 3 studies (NCT02118766/NCT02118792), mediation modeling determined the interrelationship among pruritus, quality of life (QoL), and treatment. Patients aged ≥ 2 years received crisaborole ointment, 2%, or vehicle twice daily for 28 days. QoL measures were Dermatology Life Quality Index (DLQI) (≥ 16 years) and Children{\textquoteright}s Dermatology Life Quality Index (CDLQI) (2–15 years). Pruritus was assessed by the Severity of Pruritus Scale (4-point scale from 0 to 3). The indirect effect of crisaborole on QoL mediated through its effect on pruritus was 51% (DLQI model, p < 0.05) and 72% (CDLQI model, p < 0.05). Direct effect (other effects) on QoL was 49% (DLQI model, p < 0.05) and 28% (CDLQI model, p > 0.05). Mediation modeling shows that crisaborole affects QoL mostly indirectly through pruritus severity reduction.",

keywords = "Atopic dermatitis, Crisaborole, Mediation, Pruritus, Quality of life",

author = "Simpson, {Eric L.} and Gil Yosipovitch and Bushmakin, {Andrew G.} and Cappelleri, {Joseph C.} and Thomas Luger and Sonja St{\"a}nder and Tom, {Wynnis L.} and Ports, {William C.} and Zielinski, {Michael A.} and Tallman, {Anna M.} and Huaming Tan and Gerber, {Robert A.}",

note = "Publisher Copyright: {\textcopyright} 2019 Acta Dermato-Venereologica.",

year = "2019",

month = jul,

doi = "10.2340/00015555-3181",

language = "English (US)",

volume = "99",

pages = "756--761",

journal = "Acta dermato-venereologica",

issn = "0001-5555",

publisher = "Society for the Publication of Acta Dermato-Venereologica",

number = "9",

}

TY - JOUR

T1 - Direct and indirect effects of crisaborole ointment on quality of life in patients with atopic dermatitis

T2 - A mediation analysis

AU - Simpson, Eric L.

AU - Yosipovitch, Gil

AU - Bushmakin, Andrew G.

AU - Cappelleri, Joseph C.

AU - Luger, Thomas

AU - Ständer, Sonja

AU - Tom, Wynnis L.

AU - Ports, William C.

AU - Zielinski, Michael A.

AU - Tallman, Anna M.

AU - Tan, Huaming

AU - Gerber, Robert A.

PY - 2019/7

Y1 - 2019/7

N2 - Crisaborole ointment is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis. Using pooled data from two phase 3 studies (NCT02118766/NCT02118792), mediation modeling determined the interrelationship among pruritus, quality of life (QoL), and treatment. Patients aged ≥ 2 years received crisaborole ointment, 2%, or vehicle twice daily for 28 days. QoL measures were Dermatology Life Quality Index (DLQI) (≥ 16 years) and Children’s Dermatology Life Quality Index (CDLQI) (2–15 years). Pruritus was assessed by the Severity of Pruritus Scale (4-point scale from 0 to 3). The indirect effect of crisaborole on QoL mediated through its effect on pruritus was 51% (DLQI model, p < 0.05) and 72% (CDLQI model, p < 0.05). Direct effect (other effects) on QoL was 49% (DLQI model, p < 0.05) and 28% (CDLQI model, p > 0.05). Mediation modeling shows that crisaborole affects QoL mostly indirectly through pruritus severity reduction.

AB - Crisaborole ointment is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis. Using pooled data from two phase 3 studies (NCT02118766/NCT02118792), mediation modeling determined the interrelationship among pruritus, quality of life (QoL), and treatment. Patients aged ≥ 2 years received crisaborole ointment, 2%, or vehicle twice daily for 28 days. QoL measures were Dermatology Life Quality Index (DLQI) (≥ 16 years) and Children’s Dermatology Life Quality Index (CDLQI) (2–15 years). Pruritus was assessed by the Severity of Pruritus Scale (4-point scale from 0 to 3). The indirect effect of crisaborole on QoL mediated through its effect on pruritus was 51% (DLQI model, p < 0.05) and 72% (CDLQI model, p < 0.05). Direct effect (other effects) on QoL was 49% (DLQI model, p < 0.05) and 28% (CDLQI model, p > 0.05). Mediation modeling shows that crisaborole affects QoL mostly indirectly through pruritus severity reduction.

KW - Atopic dermatitis

KW - Crisaborole

KW - Mediation

KW - Pruritus

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=85069889959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069889959&partnerID=8YFLogxK

U2 - 10.2340/00015555-3181

DO - 10.2340/00015555-3181

M3 - Article

C2 - 30896779

AN - SCOPUS:85069889959

SN - 0001-5555

VL - 99

SP - 756

EP - 761

JO - Acta dermato-venereologica

JF - Acta dermato-venereologica

IS - 9

ER -

Direct and indirect effects of crisaborole ointment on quality of life in patients with atopic dermatitis: A mediation analysis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this